Assessing cognitive effects of whole brain radiation therapy in blood cancer patients
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
This study is testing how whole brain radiation therapy affects thinking and memory in blood cancer patients, while also looking at quality of life and brain changes over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT05011045 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the neurocognitive outcomes of patients with hematologic malignancies who receive whole brain radiation therapy (WBRT). It aims to record cognitive function using standard neurocognitive tests and assess quality of life through validated questionnaires. Additionally, the study will explore MRI changes in the brain post-WBRT and investigate the role of Memantine on cognitive outcomes. Patients will undergo assessments at baseline, and then at 2, 6, 12 months, and annually for 5 years after treatment completion.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who are receiving radiation therapy for hematologic malignancies and can complete cognitive assessments in English.
Not a fit: Patients who are not receiving WBRT for hematologic malignancies or those unable to participate in cognitive assessments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the cognitive effects of WBRT, potentially leading to improved management strategies for patients undergoing this treatment.
How similar studies have performed: Other studies have explored cognitive outcomes after radiation therapy, but this specific approach focusing on hematologic malignancies is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older * Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma \[PCNSL\], secondary central nervous system lymphoma \[SCNSL\], leukemia, myeloma) * Proficient and capable of completing tests in English * Patients with claustrophobia are eligible if the claustrophobia is managed with medication * Patients with cognitively-impairment are eligible if the impairment is managed with medication * Patients who are pregnant
Where this trial is running
Houston, Texas
- M D Anderson Cancer Center — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Bouthaina S Dabaja — M.D. Anderson Cancer Center
- Study coordinator: Dustin M Silk
- Email: dmdmsilk@mdanderson.orgsilk@mdanderson.org
- Phone: 713-563-3090
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.